Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Stem Cell Research News

Untangling DNA Regulation - MIT Biologists Theorize Role For DNA Packaging In Stem Cell Development

Main Category: Stem Cell Research
Also Included In: Genetics;  Regulatory Affairs / Drug Approvals
Article Date: 07 Nov 2008 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

MIT biologists have discovered that the organization of DNA's packing material plays a critical role in directing stem cells to become different types of adult cells.

The work, to be published in the journal Cell on Nov. 14, could also shed light on the possible role of DNA packaging in cancer development.

Led by Laurie Boyer, assistant professor of biology at MIT, the researchers examined the role of chromatin - the structure that forms when DNA is wound around a core of proteins called histones.

"We're particularly interested in how chromatin structure influences gene expression and ultimately cell fate," Boyer said. "We hope the studies we are doing can lead to better understanding of development as well as certain diseases."

It has been theorized that cancer cells may overexpress genes involved in early embryonic development, allowing them to proliferate unchecked and regress from adult tissue cells to a stem cell-like state.

Such regression could be partly mediated by changes in chromatin. This packaging is believed to help control DNA transcription because the more tightly wound the chromatin is, the less accessible DNA is to be transcribed.

The new study focused on a variant type of histone known as H2AZ, which other researchers have recently identified as a protein of interest in cancer.

While H2AZ is ubiquitously expressed in many cell types including adult cells, it is known to be essential for normal embryonic development. The new research reveals why: The variant histones are found near the promoter regions of a particular set of genes that are important for development.

The same genes are also regulated by a group of proteins known as Polycomb group (PcG) proteins, which act as gene silencers.

"It suggests that this histone variant - along with the Polycomb group proteins - may act as some kind of regulatory switch that mediates cell fate transitions," Boyer said. "We hypothesize that they're working together, and that allows these genes to be silent yet poised for activation in stem cells."

In future studies, Boyer's team plans to look at patterns of H2AZ distribution in cancerous cells.

Lead authors of the paper are Whitehead Institute postdoctoral associates Menno Creyghton and Styliani Markoulaki. Other authors are Whitehead postdoctoral associates Stuart Levine and Jacob Hanna; graduate student Michael Lodato; Ky Sha, a postdoctoral associate in biology; Richard Young, professor of biology; and Rudolf Jaenisch, professor of biology and member of the Whitehead Institute.

The research was funded by the Dutch Cancer Foundation, the Helen Hay Whitney Foundation, the National Institutes of Health and Genzyme Corp.

By Anne Trafton, MIT News Office

MIT




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Forum Icon

Stem Cell Research Forum

Discuss issues relating to stem cell research in our new forum.

Visit the stem cell research forum


These are the most read articles from this news category for the last 6 months:
Top Article Star
ALS Stem Cell Trial Gets FDA Go Ahead
29 Sep 2009
The US Food and Drug Administration (FDA) said the first clinical trial to test a new stem cell treatment for the fatal neurodegenerative disease ALS (amyotrophic lateral sclerosis) this month (ALS) can go ahead...


Understanding the Autism Spectrum
Understanding the Autism Spectrum

Children with autism or related syndromes can have a variety of symptoms. But one thing they have in common is difficulty interacting socially.

more videos are available in our health videos section.